These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35393455)

  • 1. Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.
    Jones G; Ricard JA; Lipson J; Nock MK
    Sci Rep; 2022 Apr; 12(1):4099. PubMed ID: 35393455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study.
    Jones GM; Nock MK
    Sci Rep; 2022 Feb; 12(1):2574. PubMed ID: 35173246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between classic psychedelics and nicotine dependence in a nationally representative sample.
    Jones G; Lipson J; Nock MK
    Sci Rep; 2022 Jun; 12(1):10578. PubMed ID: 35732796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.
    Jones G; Arias D; Nock M
    Sci Rep; 2022 Dec; 12(1):21927. PubMed ID: 36535992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):66-73. PubMed ID: 35090364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.
    Jones G; Lipson J; Wang E
    Sci Rep; 2023 Feb; 13(1):2466. PubMed ID: 36774449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between naturalistic use of psychedelics and co-occurring substance use disorders.
    Rabinowitz J; Lev-Ran S; Gross R
    Front Psychiatry; 2022; 13():1066369. PubMed ID: 36704738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
    Johnson MW
    Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of classic psychedelics among adults: a Danish online survey study.
    Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
    Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes.
    Jones GM
    J Psychopharmacol; 2023 Jan; 37(1):61-69. PubMed ID: 36314881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationships of classic psychedelic use with criminal behavior in the United States adult population.
    Hendricks PS; Crawford MS; Cropsey KL; Copes H; Sweat NW; Walsh Z; Pavela G
    J Psychopharmacol; 2018 Jan; 32(1):37-48. PubMed ID: 29039233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies.
    Calleja-Conde J; Morales-García JA; Echeverry-Alzate V; Bühler KM; Giné E; López-Moreno JA
    Addict Biol; 2022 Nov; 27(6):e13229. PubMed ID: 36301215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.
    Mellner C; Dahlen M; Simonsson O
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use.
    Jones G; Herrmann F; Wang E
    Addict Behav Rep; 2023 Dec; 18():100513. PubMed ID: 37649653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia.
    Glynos NG; Pierce J; Davis AK; McAfee J; Boehnke KF
    J Psychoactive Drugs; 2023; 55(1):73-84. PubMed ID: 35001856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.